CliffBio
small molecule

ERLOTINIB HYDROCHLORIDE

ERLOTINIB HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyShilpa Medicare →See this company's full patent-cliff portfolio

Drug detail

Brand nameERLOTINIB HYDROCHLORIDE
Active ingredientERLOTINIB HYDROCHLORIDE
StrengthEQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2019
Marketing statusRX

More from Shilpa Medicare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ERLOTINIB HYDROCHLORIDE patent cliff — loss of exclusivity — | CliffBio